CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 6 enrolled
Drug / intervention
anakinradrug
Likely dose
anakinra 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01516749
NCT01516749Phase 2Completed
CompareCT.gov

An Open Label Non-randomized Study Assessing the Efficacy and Tolerability of Fixed-dose Regimen Daily Subcutaneous Anakinra for the Treatment of Moderate to Severe Hidradenitis Suppurativa

University of California, San Francisco·interventional·Posted Jan 25, 2012·Updated Aug 20, 2014

In Brief

A Phase 2 clinical trial evaluating anakinra for Hidradenitis Suppurativa. Completed, enrolled 6 participants across 1 site.

Detailed Summary

This is an open-label, proof-of-concept research study to assess the effectiveness of anakinra in the treatment of patients with hidradenitis suppurativa (HS). The planned intervention is to provide about 6 HS patients with anakinra 100mg daily injections to administer subcutaneously for 8 weeks. Then, the study subjects will be followed for a further 8 weeks to monitor for relapse of HS.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 25, 2012
Enrollment StartOct 1, 2012
Primary CompletionMay 1, 2013
Study CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 14.4 years ago

Interventions

anakinradrug

Anakinra is supplied in individual pre-filled glass syringes 100mg/0.67mL each. It will be injected subcutaneously once daily for 8 continuous weeks.